June 10, 2021

New FAQ on the European Medical Device Nomenclature (EMDN) to support the EUDAMED

The Medical Device Coordination Group (MDCG), composed of representatives of all Member States and a representative of the European Commission, endorsed a new FAQ on the European Medical Device Nomenclature (EMDN) intended to support the functioning of the European database on medical devices (EUDAMED). Among other things, the EMDN will be utilized by manufacturers to register medical devices in the EUDAMED, where each device will be associated with a Unique Device Identifier – Device Identifier (UDIDI).

As explained in the document, the EMDN primarily serves a regulatory purpose to support the requirements set forth by the medical device regulations (MDR and IVDR); however, it also plays a key role in MDR/IVDR device documentation and technical documentation; sampling of technical documentation conducted by notified bodies; post-market surveillance, oversight, and data analysis; and so on.

The EMDN will be particularly useful for operators once the EUDAMED is operational. The EUDAMED is the IT system developed by the European Commission to implement the MDR and IVDR. It reflects major improvements, as the EUDAMED is a much larger database than the one that currently exists under the Medical Device Directives.

The original plan provided for implementation of the EUDAMED in March 2020, but that date was later postponed by the European Commission. The EUDAMED is composed of six modules; two (the device registration module and the module on certificates and notified bodies) will become available in September 2021 (as announced by the European Commission), while the remaining modules will be available as soon as they are operational. The database is expected to be fully operational in May 2022.

< Back to blog
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the life sciences and healthcare industry.
Read more
Our highly-ranked team of professionals will provide news, insights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and venture capital transactions.

October 6, 2023
CBD products: the Administrative Court suspended until October 24 the recent Decree of the Italian Ministry of Health listing cannabidiol for oral use among narcotic drugs, due to the lack o...
October 4, 2023
The Guidelines for regulating contractual relations between universities and research institutes and private sponsors were adopted by the relevant Italian Ministries following the amendment ...
September 21, 2023
CBS products: from September 20th, compositions for oral administration of cannabidiol obtained from Cannabis sativa extracts shall be considered as narcotic drugs in Italy, as they have bee...
July 27, 2023
Payback on medical devices: Italian government announces extension of payment deadline to October 30, 2023
July 21, 2023
On July 21, 2023, the Italian Ministry of Health published new guidelines on health advertising of self-medication drugs (OTC) and non-prescription drugs (SOP), including advertising on new ...
Search by...
Follow us on
Follow us on